Targeting of interleukin-10 receptor by a potential human interleukin-10 peptide efficiently blocks interleukin-10...

Area of Science:

• Immunology
• Biochemistry
• Drug Discovery

Background:

• Human interleukin-10 (IL-10) is a critical cytokine regulating immune responses.
• IL-10's function involves binding to its receptors, IL-10Ra and IL-10Rb, to modulate cellular immunity.
• Dysregulation of IL-10 signaling is implicated in various diseases.

Purpose of the Study:

• To design and validate a peptide inhibitor targeting the IL-10/IL-10Ra interaction.
• To explore structure-based peptide design for therapeutic applications.
• To inhibit cell growth by blocking IL-10 receptor binding.

Main Methods:

• Molecular docking and structural analysis were employed to design a peptide.
• A peptide, IL10NM25, was synthesized based on computational predictions.
• Cell assays were performed to validate the peptide's binding specificity and inhibitory function.

Main Results:

• Computational simulations revealed that IL10NM25 binds to IL-10Ra primarily through electrostatic interactions.
• Cell experiments confirmed IL10NM25's specific binding to IL-10Ra on B-lineage cell lines (BJAB and lymphoblastoid).
• Mutant and scramble peptides did not inhibit IL-10/IL-10Ra binding, validating the designed peptide's efficacy.

Conclusions:

• Structure-based peptide design is a viable strategy for developing novel peptide therapeutics.
• The designed peptide IL10NM25 shows potential for inhibiting IL-10-mediated cell growth.
• This study highlights a promising approach for peptide drug discovery targeting cytokine-receptor interactions.